At a glance
- Originator Ajinomoto
- Class Antineoplastics; Stilbenes
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Oct 2004 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 08 Feb 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 31 Mar 1998 Preclinical development for Cancer in Japan (Unknown route)